CDKN2A and breast cancer: In a pivotal study, Finn and colleagues observed that BC cell lines with increased expression of Rb and cyclin D1 and downregulation of p16 at baseline were more sensitive to palbociclib, while Rb loss yielded therapeutic failure [29].